Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven cetuximab-based treatment across three lines in RAS/BRAF wild-type metastatic colorectal cancer
2024-518534-81-00Phase 2Authorised
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Gruppo Oncologico dell'Italia Meridionale. Primary endpoint: Response rate. Planned start Jul 2021; status: authorised.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-518534-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518534-81-00.